The U.S. Diabetes Care Devices Market was valued at USD 19.3 billion in 2024 and is estimated to grow at a CAGR of 12.4% to reach USD 61.4 billion by 2034.
The widespread incidence of diabetes, combined with a growing aging population and the rise in sedentary lifestyles, is creating an urgent need for effective management tools. As individuals with diabetes require consistent monitoring and control of their blood glucose levels to prevent complications such as heart disease, kidney failure, and nerve damage, the demand for advanced diabetes care devices continues to surge.
Major players in the U.S. diabetes care devices market are Abbott Laboratories, Sinocare, Medtronic, Tandem Diabetes Care, Bionime, Dexcom, Eli Lilly and Company, F. Hoffmann-La Roche, LifeScan, Becton, Dickinson and Company, DarioHealth, Ypsomed Holding, Insulet, Nova Biomedical, Novo Nordisk, Ascensia Diabetes Care, Dr. Reddy’s Laboratories, ARKRAY, and B. Braun Melsungen.
Leading companies in the diabetes care devices market are heavily investing in research and development (R&D) to create innovative products that offer better accuracy, convenience, and integration with digital health tools. For instance, companies like Abbott Laboratories and Dexcom have introduced advanced continuous glucose monitoring (CGM) systems with real-time data syncing, enabling patients and healthcare providers to make more informed decisions. These advancements aim to improve patient outcomes and drive long-term market growth. Many companies are forming strategic partnerships with healthcare providers, technology companies, and insurance firms to expand their reach and access to new customer segments.
This product will be delivered within 2-4 business days.
The widespread incidence of diabetes, combined with a growing aging population and the rise in sedentary lifestyles, is creating an urgent need for effective management tools. As individuals with diabetes require consistent monitoring and control of their blood glucose levels to prevent complications such as heart disease, kidney failure, and nerve damage, the demand for advanced diabetes care devices continues to surge.
Rising Adoption of Devices
The devices segment held a notable share in 2024, encompassing blood glucose meters, test strips, insulin pens, insulin pumps, and continuous glucose monitoring (CGM) systems. Companies are responding by introducing localized, cost-effective devices with smart features such as Bluetooth connectivity and mobile app integration. To strengthen their foothold, leading players are forming partnerships with local distributors, expanding regional manufacturing, and customizing product lines to meet cultural and economic preferences in urban and rural markets alike.Homecare to Gain Traction
The home care segment in the U.S. diabetes care devices market generated a significant share in 2024 as more patients shifted toward self-management and at-home monitoring. Factors such as the rising cost of in-clinic care, growing health consciousness, and the increasing prevalence of type 2 diabetes among middle-aged adults have all contributed to this trend. Companies are prioritizing ease of use, portability, and affordability while ensuring accuracy and reliability. Key strategies to capture this segment include launching direct-to-consumer online platforms, offering multilingual user support, and partnering with digital health apps to deliver personalized insights and remote monitoring capabilities.Major players in the U.S. diabetes care devices market are Abbott Laboratories, Sinocare, Medtronic, Tandem Diabetes Care, Bionime, Dexcom, Eli Lilly and Company, F. Hoffmann-La Roche, LifeScan, Becton, Dickinson and Company, DarioHealth, Ypsomed Holding, Insulet, Nova Biomedical, Novo Nordisk, Ascensia Diabetes Care, Dr. Reddy’s Laboratories, ARKRAY, and B. Braun Melsungen.
Leading companies in the diabetes care devices market are heavily investing in research and development (R&D) to create innovative products that offer better accuracy, convenience, and integration with digital health tools. For instance, companies like Abbott Laboratories and Dexcom have introduced advanced continuous glucose monitoring (CGM) systems with real-time data syncing, enabling patients and healthcare providers to make more informed decisions. These advancements aim to improve patient outcomes and drive long-term market growth. Many companies are forming strategic partnerships with healthcare providers, technology companies, and insurance firms to expand their reach and access to new customer segments.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2024
Chapter 5 Market Estimates and Forecast, by Product, 2021-2034 ($ Mn)
Chapter 6 Market Estimates and Forecast, by End Use, 2021-2034 ($ Mn)
Chapter 7 Company Profiles
Companies Mentioned
The key companies profiled in this U.S. Diabetes Care Devices market report include:- Abbott Laboratories
- ARKRAY
- Ascensia Diabetes Care
- B. Braun Melsungen
- Becton, Dickinson and Company
- Bionime
- DarioHealth
- Dexcom
- Dr. Reddy’s Laboratories
- Eli Lilly and Company
- F. Hoffmann-La Roche
- Insulet
- LifeScan
- Medtronic
- Nova Biomedical
- Novo Nordisk
- Sanofi
- Sinocare
- Tandem Diabetes Care
- Ypsomed Holding
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 68 |
| Published | September 2025 |
| Forecast Period | 2024 - 2034 |
| Estimated Market Value ( USD | $ 19.3 Billion |
| Forecasted Market Value ( USD | $ 61.4 Billion |
| Compound Annual Growth Rate | 12.4% |
| Regions Covered | United States |
| No. of Companies Mentioned | 21 |
